Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 ·Status: UNKNOWN

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NCT03861156 ·Status: COMPLETED ·Phase: PHASE2

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217 ·Status: UNKNOWN

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

NCT02737774 ·Status: UNKNOWN ·Phase: PHASE2

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NCT04201756 ·Status: COMPLETED ·Phase: PHASE2

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058 ·Status: UNKNOWN ·Phase: PHASE2

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

NCT02575560 ·Status: COMPLETED

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

NCT04132102 ·Status: UNKNOWN ·Phase: PHASE4

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

NCT04426825 ·Status: COMPLETED ·Phase: PHASE2

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

NCT01746277 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer

NCT01100840 ·Status: UNKNOWN

Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC

NCT03300115 ·Status: UNKNOWN ·Phase: PHASE2

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

NCT05219162 ·Status: COMPLETED ·Phase: PHASE4

Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

NCT01000740 ·Status: COMPLETED ·Phase: PHASE4

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

NCT05020457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3

A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response

NCT01523340 ·Status: COMPLETED

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

NCT04204473 ·Status: COMPLETED ·Phase: PHASE1

Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

NCT01648517 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING